Galen — a privately owned pharmaceutical company — seeks partnerships and acquisitions to drive forward its growth ambitions and build on proud legacy

dennise_broderick_galen_large-1

Not many companies in the pharmaceutical sector can say that they have kept growing and targeting growth through the pandemic, while maintaining the same commitment to their values, patients and employees.

But Galen — a privately-owned global pharmaceutical sales and marketing company and part of Northern Irish pharma success story Almac Group — can certainly make that claim. The company is pursuing an ambitious plan to expand across new territories and therapeutic areas via acquisition, with particular sights set on further expansion into the USA and Europe.

It was Galen’s growth ambitions — coupled with its legacy, patient-centric core products and real potential to build — that attracted Dennise Broderick (pictured) to take on the role of Managing Director and President about three years ago.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical